{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypereosinophilia+Syndrome+%28HES%29",
    "query": {
      "condition": "Hypereosinophilia Syndrome (HES)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:05:25.889Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02130882",
      "title": "Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Respiratory System Agents",
        "Anti-Asthmatic Agents",
        "Hematologic Diseases",
        "Leukocyte Disorders",
        "Hypereosinophilia"
      ],
      "interventions": [
        {
          "name": "benralizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-05-19",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-05-22T04:05:25.889Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02130882"
    },
    {
      "nct_id": "NCT01524536",
      "title": "Steroid Treatment for Hypereosinophilic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Eosinophilia",
        "Hypereosinophilic Syndrome",
        "Leukocyte Disorder",
        "Hematologic Diseases"
      ],
      "interventions": [
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "7 Years to 100 Years"
      },
      "enrollment_count": 26,
      "start_date": "2012-02-16",
      "completion_date": "2020-12-10",
      "has_results": true,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-05-22T04:05:25.889Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524536"
    },
    {
      "nct_id": "NCT00086658",
      "title": "Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypereosinophilia",
        "Hypereosinophilic Syndrome"
      ],
      "interventions": [
        {
          "name": "mepolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 86,
      "start_date": "2004-03-23",
      "completion_date": "2006-05-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-05",
      "last_synced_at": "2026-05-22T04:05:25.889Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Denver, Colorado • Bethesda, Maryland + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00086658"
    },
    {
      "nct_id": "NCT06512883",
      "title": "A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Granulomatosis With Polyangiitis (EGPA)",
        "Hypereosinophilia Syndrome (HES)"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 14,
      "start_date": "2025-04-17",
      "completion_date": "2028-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-05-22T04:05:25.889Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Highland Hills",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06512883"
    }
  ]
}